Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2018

View Archived Issues

FDA approves IND application for clinical study of RK-01

FDA approves Rituxan for moderate to severe pemphigus vulgaris

NOSO-502: a new antibacterial drug candidate active against carbapenem-resistant Enterobacteriaceae

Bayer closes its acquisition of Monsanto

Modest data for PI3K inhibitor taselisib in breast cancer

Dana-Farber Cancer Institute patents new PROTAC compounds for cancer

Bristol-Myers Squibb divulges integrin alphaV antagonists

Prolia approved in Europe for patients with glucocorticoid-induced osteoporosis

Merck & Co. identifies Nav1.7 channel blockers

Amgen presents new apelin receptor agonists

Rapalimus gel launched in Japan for the treatment of angiofibromas in tuberous sclerosis

FDA approves Venclexta plus rituximab for previously treated CLL and SLL

Idorsia initiates phase II registration program for nemorexant in insomnia

EBX-205, a new oral broad-spectrum antibiotic active against bioterrorism pathogens

Evgen offers interim update from phase II STEM trial of SFX-01 in advanced breast cancer

Tagrisso approved in E.U. for first-line EGFR-mutated NSCLC

Responses to M-7824 in phase I study lead to phase II trial in HPV-associated cancers

MaxCyte and NIH enter CRADA for sickle cell disease

First-in-human study evaluates AZD-4205 with osimertinib in advanced NSCLC

Saniona to study Tesomet in phase IIa trial for hypothalamic obesity

NeuroVia initiates phase I/II trial of NV-1205 in childhood cerebral adrenoleukodystrophy

Pfizer initiates phase II study of PF-06730512 in primary focal segmental glomerulosclerosis

Taiho studies TAS-0728 in solid tumors with HER2 or HER3 abnormalities

SHP2, a potential therapeutic target in KRAS-mutant tumors

FDA clears IND for phase I trial of CK-0801 for bone marrow failure syndromes